-
公开(公告)号：EP3468633A1
公开(公告)日：2019-04-17
申请号：EP17734567.5
申请日：2017-06-13
发明人： DOLOFF, Joshua , XIE, Xi , YESILYURT, Volkan , VEISEH, Omid , SADRAEI, Atieh , ANDERSON, Daniel, G. , LANGER, Robert, S.
IPC分类号： A61L31/10 , A61B5/145 , A61B5/1486
-
公开(公告)号：EP2814460B1
公开(公告)日：2018-06-27
申请号：EP13708563.5
申请日：2013-02-19
CPC分类号： A61K38/28 , A61K9/0019 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K9/5138 , A61K9/5161 , A61K38/44 , A61K38/443 , C12Y101/03004 , C12Y111/01006 , A61K2300/00
摘要： Injectable insulin loaded microgels that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these compositions have been developed. The microgels contain insulin, glucose oxidase entrapped in or bound to the microgels, and an agent that reduces hydrogen peroxide, entrapped in or bound to the microgels, wherein the polymeric microgel expands when pH decreases from physiological pH and shrinks when pH increases towards physiological pH, thereby releasing insulin at a rate corresponding to the glucose concentration. In one embodiment, the glucose oxidase and/or the agent reducing hydrogen peroxide are encapsulated in nanogels, then encapsulated within the microgel.
-
3.发明公开MULTI-LAYER HYDROGEL CAPSULES FOR ENCAPSULATION OF CELLS AND CELL AGGREGATES 审中-公开用于细胞和细胞融合的多层水凝胶胶囊
公开(公告)号：EP3297693A1
公开(公告)日：2018-03-28
申请号：EP16730071.4
申请日：2016-05-17
发明人： MA, Minglin , ANDERSON, Daniel, G. , LANGER, Robert, S. , VEISEH, Omid , VEGAS, Arturo, Jose , DOLOFF, Joshua, Charles , CHEN, Delai , KASTRUP, Christian, J.
CPC分类号： A61L27/20 , A61F2/02 , A61F2230/0071 , A61F2240/001 , A61F2250/0068 , A61L27/3804 , A61L27/52 , A61L27/54 , A61L2300/64 , A61L2400/18 , A61M31/002 , A61M2205/04 , A61M2207/00
摘要： Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
-
公开(公告)号：EP1024801B1
公开(公告)日：2004-06-23
申请号：EP98967012.0
申请日：1998-10-30
IPC分类号： A61K31/335 , A61P43/00
CPC分类号： A61K38/484 , A61K31/00 , A61K31/336 , A61K31/454 , A61K38/39
-
公开(公告)号：EP0868508A1
公开(公告)日：1998-10-07
申请号：EP96937894.0
申请日：1996-10-31
CPC分类号： C12N13/00 , A61L31/048 , A61L31/06 , A61L31/14 , C12M25/08 , C12M35/02 , C12M35/08 , C12N5/0068 , C12N2533/30 , C12N2533/40 , A61B17/11 , C08L79/02 , C08L81/00 , C08L45/00
摘要： Methods and support systems are provided for modifying the regeneration, differentiation, or function of cells. In one embodiment, electrically conducting biocompatible polymers may be used alone or in combination with a polymeric support for in vitro nerve cell regeneration, or in vivo to aid in healing nervous tissue defects. The conductive polymers may be implanted adjacent to or seeded with nerve cells. Voltage or current is applied to the polymer in a range which induces the desired effect on the cells while not damaging the cells. The methods and systems can be used in a variety of applications to enhance in vivo or in vitro growth or regeneration of nervous tissue.
-
6.发明授权
公开(公告)号：EP0610423B1
公开(公告)日：1997-05-07
申请号：EP92924131.3
申请日：1992-10-28
发明人： STEIN, James, E. , GILBERT, James, C. , INGBER, Donald, E. , LANGER, Robert, S. , VACANTI, Joseph, P.
CPC分类号： A61L27/3886 , A61F2/02 , A61F2/022 , A61L27/38 , A61L27/3804 , A61L27/56 , C12N5/00
摘要： A method is disclosed whereby cells having a desired function are seeded on and into biocompatible, biodegradable or non-degradable polymer scaffolding, previously implanted in a patient and infiltrated with blood vessels and connective tissue, to produce a functional organ equivalent. The resulting organoid is a chimera formed of parenchymal elements of the donated tissue and vascular and matrix elements of the host. The matrix should be a non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, should allow vascular and connective tissue ingrowth throughout approximately 10 to 90 % of the matrix, and the injection of cells such as hepatocytes without damage to the cells or patient. The introduced cells attach to the connective tissue and are fed by the blood vessels. Immediately prior to polymer implantation portacaval shunts can be created to provide trophic stimulatory factors to the implants to enhance replication and function.
-
公开(公告)号：EP0259463B1
公开(公告)日：1992-04-29
申请号：EP87902003.0
申请日：1987-03-05
CPC分类号： G01N33/86 , C12Q1/56 , G01N2400/40 , Y10S435/81
摘要： The level of heparin in a blood sample is measured by measuring the clotting time of two aliquots of the blood sample, using standard clotting assays, with one of the aliquots being firstly treated with a heparin-degrading compound, such as heparinase. The difference in clotting times is a direct measure of the heparin concentration in the sample.
-
公开(公告)号：EP3368596A1
公开(公告)日：2018-09-05
申请号：EP16816769.0
申请日：2016-11-01
发明人： VEGAS, Arturo, Jose , DOLOFF, Joshua, Charles , VEISEH, Omid , LANGER, Robert, S. , ANDERSON, Daniel, G.
IPC分类号： C08J7/12
CPC分类号： A61L27/3804 , A61K9/0051 , A61K35/12 , A61K35/36 , A61K38/02 , A61L27/04 , A61L27/10 , A61L27/16 , A61L27/18 , A61L27/20 , A61L27/34 , A61L27/3813 , A61L27/3839 , A61L27/54 , A61L27/56 , A61L29/14 , A61L2300/252 , A61L2300/254 , A61L2400/18 , C08J7/12
摘要： Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.
-
公开(公告)号：EP2482922A1
公开(公告)日：2012-08-08
申请号：EP10821224.2
申请日：2010-09-30
申请人： Massachusetts Institute of Technology , President and Fellows of Harvard College , Children's Medical Center Corporation
CPC分类号： A61K9/0009 , A61K9/5138 , A61K9/5146 , A61K9/5153 , A61K41/0042 , A61K47/6921 , A61K47/6935 , A61N5/0601 , A61N5/062
摘要： The present invention relates, in part, to a novel and simple particulate system that targets and binds any tissue selectively upon light illumination. The particulate system can be used for targeted delivery of substances to predefined cells or tissues in an individual.
-
公开(公告)号：EP0797460A1
公开(公告)日：1997-10-01
申请号：EP95943847.0
申请日：1995-12-15
CPC分类号： A61L27/3804 , A61F2/12 , A61F2002/0086 , A61F2250/0003 , A61L27/3839 , A61L2430/04
摘要： Methods and compositions are described herein for reconstruction or augmentation of breast tissue. Dissociated cells, preferably muscle cells, are implanted in combination with a suitable biodegradable, polymeric matrix to form new tissue. There are two forms of matrices which can be used: a polymeric hydrogel formed of a material such as alginate having cells suspended therein, and a fibrous matrix having an interstitial spacing between about 100 and 300 microns. Preferred polymeric materials are those degrading over about one to two months, such as polylactic acid-glycolic acid copolymers. The matrices can be seeded prior to implantation or implanted, allowed to vascularize, then seeded with cells. In a preferred embodiment, the cell-matrix structures are implanted in combination with tissue expander devices. As cell-matrix is implanted, or cells proliferate and form new tissue, the expander size is decreased, until it can be removed and the desired reconstruction or augmentation is obtained. The preferred cell types are muscle cells, although other types of mesenchymal cells, fibroblasts, chondrocytes, and adipocytes can be used. Cells obtained from tissue such as the labia can be used for specialized applications such as formation of a nipple type tissue. Other materials, such as bioactive molecules that enhance vascularization of the implanted tissue and/or which inhibit ingrowth of fibrotic tissue, can be implanted with the matrix to enhance development of more normal tissue.
-
-
-
-
-
-
-
-
-
搜索结果
127 条记录 (耗时 0.032 秒)
